EPTIFIBATIDE

Synonyms. Eptifibatide; Integrelin; Integrilin; N(6)-Amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L- alpha-aspartyl-L-tryptophyl-L-prolyl-L- cysteinamide, cyclic(1-6)-disulfide; c[Mpa-Har-Gly-Asp-Trp-Pro-Cys]-NH2;

 EPTIFIBATIDE

 

PRODUCT IDENTIFICATION

CAS RN

 188627-80-7 (free base), 148031-34-9 (acetate)

EINECS RN

  

FORMULA

 C35H49N11O9S2

MOLE WEIGHT

 831.96

H.S CODE

  

SMILES

 c1ccc2c(c1)c(c[nH]2)C[C@H]3C(= O)N4CCC[C@@H]4C(=O )N[C@ H] (CSS CCC(=O)N[C@@H](C(=O )NCC(=O)N[C@@H](C(=O)N3)CC(=O) O)CC CCN C(=N)N) C(=O)N

CLASSIFICATION

 Hematologic, Platelet Aggregation Inhibitor

EXTRA NOTES

 Used in clinical studies as a platelet glycoprotein IIB/IIIA antagonist.

OTHER RN

148031-34-9, 157630-07-4

 

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE.

powder

MELTING POINT

 

BOILING POINT

 

DENSITY

 

SOLUBILITY IN WATER

 

SOLVENT SOLUBILITY  

VAPOR DENSITY

 

log P(octanol-water)

  

VAPOR PRESSURE

  

AUTOIGNITION TEMP

  
pH

 

REFRACTIVE INDEX

 

FLASH POINT

 

 
STABILITY AND REACTIVITY
STABILITY Stable under normal conditions.

INCOMPATIBLE MATERIALS

Strong oxidizing agents

POLYMERIZATION

Has not been reported

NFPA RATINGS

Health: 2,Flammability:1, Reactivity: 0

 

EXTERNAL LINKS & GENERAL DESCRIPTION

Wikipedia Linking - Eptifibatide

Google Scholar Search - Eptifibatide

Drug Information Portal (U.S. National Library of Medicine) - Eptifibatide

PubChem Compound Summary - Eptifibatide

Drug Bank -  Eptifibatide

KEGG (Kyoto Encyclopedia of Genes and Genomes) - Eptifibatide

http://www.ebi.ac.uk/ - Eptifibatide

http://www.ncbi.nlm.nih.gov/ - Eptifibatide

http://www.pbm.va.gov/
The glycoprotein IIb/IIIa receptor inhibitors, abciximab, eptifibatide, and tirofiban, all have similar mechanisms of action to inhibit the platelet aggregation process. Abciximab is a chimeric monoclonal antibody that interferes with platelet aggregation by steric hindrance. Abciximab molecules are large and possess a high degree of platelet affinity. These molecules wrap around each platelet to prevent binding of not only glycoprotein IIb/IIIa receptors important for platelet aggregation, but also other receptors responsible for platelet adhesion to the subendothelium (ie vitronectin). By preventing both platelet adhesion and aggregation, abciximab may result in more bleeding complications than more specific GP IIb/IIIa inhibitors. Tirofiban and eptifibatide are small, synthetic molecular structures that have high affinity only for the glycoprotein IIb/IIIa binding site. These compounds compete with fibrinogen for the glycoprotein IIb/IIIa receptor in a concentration-dependent manner and bind in its place, preventing platelet aggregation (figure 2). The goal of all three drugs is to achieve 80% inhibition of platelet aggregation to maximize benefits and minimize adverse effects such as bleeding.

http://www.revespcardiol.org/
Eptifibatide blocks the increase in C-reactive protein values that is routinely observed after coronary angioplasty. Since this drug selectively and specifically blocks the GP IIb/IIIa receptor, and has no other known effect, it must be concluded that the mechanism by which CRP increases after angioplasty is of a thrombotic type

 

SALES SPECIFICATION

APPEARANCE

white powder

ASSAY

95.0~105.0% (on Anhydrous, Acetic Acid free basis)

OPTICAL ROTATION

-78.0° ~ -88.0° (c=1,1% HAc)

WATER

8.0% max (Karl Fischer)

ACETATE CONTENT

15.0% max (HPLC)

AMINO ACID COMPOSITION

±10% theoretical

INDIVIDUAL IMPURITY

1.0% max (HPLC)

PEPTIDE CONTENT

80% min (by %N)

BACTERIAL ENDOTOXINS

5EU/mg max

 

TRANSPORT & REGULATORY INFORMATION

UN NO.

Not known

HAZARD CLASS

  
PACKING GROUP  

 

SAFETY INFORMATION

HAZARD OVERVIEW

Avoid contact and inhalation. May causes eye irritation. May causes skin irritation. May cause gastrointestinal irritation. May causes respiratory tract irritation
HAZARD CODES

 

RISK PHRASES

  

SAFETY PHRASES

22-24/25

 

PACKING